Science1 distinct publisher3 min readUpdated
A screen of 337 virus genomes found stabilizing elements; one, Pt1, pushed linear mRNA half-life from 7.6 to 23.1 hours by recruiting nuclear poly(A) polymerases in the cytoplasm.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
A team at the Institute for Basic Science's Center for RNA Research, led by Director Kim V. Narry, has reported in Cell a set of compact viral RNA elements that make mRNA more stable and raise protein output [1][2]. That matters because the short life of mRNA inside cells is one of the hard constraints on dosing for vaccines and protein-replacement therapies, and this result frames it as a sequence-design problem rather than a property of the molecule [4][18].
The approach was brute force. The researchers cut genomes from 337 vertebrate-infecting viruses into nearly 200,000 short segments, roughly 590 per genome, and measured each one's effect on mRNA abundance, translation and protein production [5][17]. Hundreds of segments increased gene expression [5].
Many of the hits worked through a single host enzyme, terminal nucleotidyltransferase 4, which slows degradation by extending the poly(A) tail through mixed tailing [6]. The team pinned down 23 TENT4-dependent elements spread across 19 viral genera and sorted them into six types by sequence, structure and cofactor use [7]. They call elements that promote poly(A)-tail extension "tailons" [8]. Nineteen genera converging on the same host machinery by six structural routes is the more interesting scientific finding here: it suggests the pathway is unusually easy for evolution to find, and by extension for engineers to reuse [7].
The most potent element, Pt1, does not use TENT4 at all [9]. Derived from Potamipivirus, it directly recruits poly(A) polymerase gamma and poly(A) polymerase alpha [9][10]. Those enzymes are known for tailing pre-mRNA in the nucleus; the researchers report that a fraction of both sits in the cytoplasm, where Pt1 pulls them in to extend the tail after transcription [11]. If that holds up, it is a new job description for a well-studied pair of enzymes [11].
The practical comparison is against circular RNA, which resists degradation because its ends are joined but produces protein less efficiently and is harder to manufacture [12]. In cultured cells, conventional linear mRNA had a half-life of about 7.6 hours, linear mRNA carrying Pt1 reached 23.1 hours, and circular RNA 24.9 hours [13]. That is roughly a threefold gain for a single inserted element [14], landing at about 93 percent of the circular benchmark while keeping linear mRNA's translation efficiency and simpler production [15][12].
Two caveats sit on the face of the report. The half-life comparison is in cultured cells [13], and the announcement does not extend it to animals or to dose-sparing in a formulated product [16]. The researchers also point to earlier work of their own in Nature Biotechnology, though the available description of that study is incomplete [19].
What to watch: whether the 23.1-hour figure survives lipid-nanoparticle delivery and in vivo measurement, where nuclease environments and innate immune sensing differ from a dish [13]; whether longer-lived mRNA translates into lower doses rather than merely longer expression [18]; and whether recruiting PAPγ and PAPα into cytoplasmic tailing perturbs the cell's own mRNA pool, since those enzymes have day jobs [10][11]. The six tailon classes also give developers a menu rather than a single sequence, which matters if any one element proves immunogenic or patent-encumbered [7].
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
A research team led by Director Kim V. Narry at the Center for RNA Research within the Institute for Basic Science (IBS) discovered compact viral RNA elements that can make mRNA more stable and increase protein production.
Conventional mRNA is inherently short-lived and is rapidly degraded inside cells, often limiting protein production to a relatively short period; a major factor determining stability is the poly(A) tail, and as the tail shortens the mRNA becomes increasingly vulnerable to degradation.
Delivering synthetic mRNA into cells temporarily turns them into protein-producing factories; this principle enabled COVID-19 mRNA vaccines and holds promise for cancer immunotherapy and treatments replacing proteins that are missing or insufficient.
The researchers divided genomes from 337 vertebrate-infecting viruses into nearly 200,000 short segments and tested how each affected mRNA abundance, translation and protein production; the screen revealed hundreds of viral RNA segments capable of enhancing gene expression.
Many of the identified elements relied on the cellular enzyme terminal nucleotidyltransferase 4 (TENT4), which can protect mRNA by extending its poly(A) tail through mixed tailing, slowing RNA degradation.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Single-source announcement of a peer-reviewed screen with specific quantitative results
The underlying work is described as published in Cell and reports concrete, checkable quantities: 337 viral genomes, ~200,000 segments, 23 TENT4-dependent elements across 19 genera in six classes, and half-lives of 7.6, 23.1 and 24.9 hours. A prior Nature Biotechnology study adds mouse durability and ~9x protein output. All of it, however, reaches us through one institutional press announcement with no DOI, no primary-paper text, and no independent expert or replication, and the headline stability comparison is a cultured-cell assay.
No adoption signal in supplied material
The supplied source reports no third-party use of tailons or Pt1: no licensing, partnership, company program, clinical trial, regulatory filing, manufacturing deployment or external replication. Compatibility with N1-methylpseudouridine and with existing manufacturing is asserted as a property, not evidenced as uptake, so no adoption level can be scored without inventing facts.
Forward-looking therapeutic framing runs ahead of a cultured-cell headline result
The announcement's frame ('open new possibilities', broadening mRNA beyond vaccines to cancer, immune and protein-replacement therapy, potentially lowering dose-related side-effect risk) is conditional language layered on a cell-culture half-life comparison plus earlier mouse work. The measured claims themselves are precise and modestly stated, and mouse durability data does exist, which keeps the gap moderate rather than large; the overstatement is in leaping from stability metrics to therapeutic and dosing benefit with no formulated product, no clinical evidence, and no safety analysis of viral-derived inserts.
Institution-authored announcement promoting its own result and coining its own terminology
The text is an IBS Center for RNA Research announcement carried by an aggregator: it credits its director by name, introduces a house term ('tailons') for the element class, positions the finding against circular RNA on stability, efficiency and manufacturing, and closes with a broad application pitch. That is a clear promotional incentive around funding, priority and platform positioning. No commercial sponsor, patent, equity or licensing interest is disclosed in the supplied material, so the reading rests on institutional self-promotion alone rather than evidenced financial conflict.
Internally consistent but unverified and single-sourced
Confidence is capped by having one publisher, one voice and no primary document: nothing in the cluster can be triangulated. It is supported by the specificity and internal consistency of the reported figures and by the named peer-reviewed venues. It is further reduced by two ledger entries whose scope assertions conflict with the retained body, indicating the source material itself was captured incompletely at some point.
science
Coating the liver's capillaries for a few hours redirects mRNA nanoparticles to the spleen1 distinct publisher
science
What you expect from your own old age shows up a decade later in who you still see1 distinct publisher
science
Eastern US extreme rain is pooling into fewer, wider storms, and station records hide it1 distinct publisher
science
A named ship and a published timetable turn the Arctic into a bookable lane1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 14, 2026